Zevra Therapeutics, Inc , a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.
infoZevra Therapeutics is a micro cap stock with a total market cap of 170.68M.
infoThey trade on the NASDAQ and had their IPO 8 years and 4 months ago.
infoZevra Therapeutics currently employs 32 people.
infoAs of Wednesday, Aug 23 2023, Zevra Therapeutics’s share price is $5.03.
News Relating to Zevra Therapeutics
GlobeNewsWire
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
Wednesday Aug 02 2023 at 07:30
CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that it will host a conference call and live audio webcast on Monday, August 14, 2023, at 8:30 a.m. ET, to review its corporate and financial results for the second quarter of 2023.
GlobeNewsWire
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
Tuesday Jun 13 2023 at 07:30
CELEBRATION, Fla., June 13, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced executive management will participate in the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, Tuesday, June 20 through Thursday, June 22, 2023.
Zacks Investment Research
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
Monday May 15 2023 at 18:59
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.06 per share a year ago.
GlobeNewsWire
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023
Wednesday May 10 2023 at 07:30
CELEBRATION, Fla., May 10, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that R. LaDuane Clifton, the Company’s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET. In addition, members of Zevra’s management team will be available for one-on-one investor meetings with registered attendees during the conference from May 16-17, 2023.
GlobeNewsWire
Zevra Therapeutics to Report First Quarter 2023 Results on May 15, 2023
Tuesday May 09 2023 at 07:30
CELEBRATION, Fla., May 09, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced that it will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET, to review its corporate and financial results for the first quarter of 2023.
Seeking Alpha
Zevra Therapeutics, Inc. (ZVRA) Q4 2022 Earnings Call Transcript
Friday Mar 10 2023 at 15:24
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Nichol Ochsner – Vice President of Investor Relations Richard Pascoe – CEO LaDuane Clifton – Chief Financial Officer Travis Mickle – President and Co-Founder Christal Mickle – Chief Product Development Officer and Co-Founder Joshua Schafer – Chief Commercial Officer and Executive Vice President, Business Development Conference Call Participants Jonathan Aschoff – ROTH MKM Partners Louise Chen – Cantor Fitzgerald Oren Livnat – H.C. Wainwright Operator Good day, and welcome to the Zevra Therapeutics Fourth Quarter and Full Year 2022 Update Call.
GlobeNewsWire
Zevra Therapeutics to Present at 35th Annual Roth Conference
Monday Mar 06 2023 at 07:30
CELEBRATION, Fla., March 06, 2023 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (“Zevra” or the “Company” and formerly KemPharm, Inc.), a rare disease therapeutics company, today announced that Richard W. Pascoe, the Company’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT. In addition, Zevra management will be available for in-person or virtual one-on-one investor meetings during the conference from March 12-14.
Zevra Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Zevra Therapeutics’s Altman Z-score is -0.98 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Zevra Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Zevra Therapeutics.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Data is unavailable for Income Quality
Data is unavailable for Current Ratio
Value Analysis
Data is unavailable for PE Ratio
Data is unavailable for PB Ratio
Efficiency Analysis
Data is unavailable for ROE
Data is unavailable for ROCE